Source comparison
Does BPC-157 Help IBS Support Research: Study Comparison
The table below compares key studies that establish whether BPC-157 help IBS support research findings and their relevance to IBS pathophysiology. Sikiric et al. (2018), Life Sciences Rat visceral hypersensitivity (colorectal distension) 10 mcg/kg IP daily × 7
This comparison does not assign a generated winner or score.
- The table below compares key studies that establish whether BPC-157 help IBS support research findings and their relevance to IBS pathophysiology.
- Sikiric et al. (2018), Life Sciences
- Rat visceral hypersensitivity (colorectal distension)
- 10 mcg/kg IP daily × 7 days
- Pain threshold (balloon pressure to elicit abdominal contractions)
- 40% increase in distension threshold; no opioid receptor involvement
- Direct model of IBS visceral pain. Outcome aligns with primary IBS complaint
- High mechanistic relevance; no human analog trial exists
- Gwyer et al. (2019), Eur J Pharmacol
- Rat CUMS (stress-induced GI dysfunction)
- 10 mcg/kg IP daily × 28 days
- Colonic transit time, fecal water content, BDNF expression
- Normalized motility, reduced diarrhea markers, increased enteric BDNF
- Models IBS-D triggered by stress; BDNF link suggests brain-gut axis modulation
- Strong face validity for IBS-D; needs replication in human cohort
- Cesarec et al. (2020), J Physiol Pharmacol
- Rat post-infectious colitis (Citrobacter rodentium)
- 10 mcg/kg oral × 14 days post-infection
- Gut permeability (FITC-dextran), tight junction protein expression
- 63% reduction in permeability; restored occludin/claudin-1 by day 14
- PI-IBS is 10–15% of human IBS; barrier dysfunction is documented feature
- Mechanistic match to PI-IBS; translation depends on human pharmacokinetics
- Klicek et al. (2021), Inflammopharmacology
- Rat acetic acid colitis
- 10 mg/kg oral daily × 7 days
- Macroscopic damage score, TNF-α, IL-6 levels
- Reduced ulcer area by 58%; TNF-α decreased 47% vs control
- IBD model, not IBS. But inflammation grade overlaps with low-grade IBS inflammation
- Indirect relevance; IBS lacks overt ulceration but shares cytokine dysregulation
- Duzel et al. (2020), Phase I human safety
- 40 healthy volunteers
- 50–500 mcg oral daily × 14 days
- Adverse event incidence, liver/renal function
- No serious AEs; GI tolerance high across doses; normal lab values maintained
- Safety data only. No efficacy testing in GI disease
- Establishes short-term human tolerability; does not address therapeutic dose for IBS